Eris Lifesciences Share Price Target 2026 — Analyst Forecast, Catalysts and Key Risks
- April 23, 2026
- Posted by: Kashish Aggarwal
- Category: News
The Eris Lifesciences share price target 2026 stands at Rs 1,102-1,282 as per analyst consensus — implying 20-39% upside from the current CMP of Rs 922. Investors tracking the Eris Lifesciences share price target 2026 need to understand the complete picture — the specific growth catalysts, FY27 earnings timeline, risks, and the bull vs bear case that will determine whether Eris Lifesciences (ERIS) achieves or misses this 12-month target. This article covers every dimension of the Eris Lifesciences share price target 2026 thesis — catalysts, risks, scenarios, analyst ratings, and key levels — updated April 2026.
Click Here — Get Free SEBI-registered Research on Eris Lifesciences on Univest.
Eris Lifesciences Share Price Overview — April 2026
| Company | Eris Lifesciences |
| NSE Symbol | ERIS |
| Sector | Pharma / Chronic Therapy / Lifestyle Diseases |
| CMP April 2026 | Rs 922 |
| 52-Week High | Rs 1,302 |
| 52-Week Low | Rs 752 |
| Market Cap | Rs 12,600 Cr |
| Trailing P/E | 22x |
| Dividend FY26 | Rs 5 |
| Promoter Holding | 52.6% |
| FII Holding | 14.8% |
| 12M Analyst Target | Rs 1,102-1,282 |
| Upside from CMP | 20-39% |
Data from NSE/BSE and publicly available research. April 2026. Verify before investing.
Track live Eris Lifesciences price, FII/DII flows and analyst targets on the Univest Screener.
What Is Eris Lifesciences?
Get Free Analyst Research on Eris Lifesciences — Tap Here.
Eris Lifesciences (NSE: ERIS) focuses on chronic therapy — diabetes, cardiovascular, CNS. Consistent 20%+ EBITDA margins through brand investment and doctor relationships. FY26 revenue Rs 1,800+ crore with chronic portfolio growing 18% YoY.
Budget 2026-27 Impact on Pharma
Budget 2026’s expanded insurance for chronic disease treatment directly benefits Eris — 70%+ revenues from diabetes and cardiovascular prescriptions.
Eris Lifesciences share price target 2026 — Short, 12-Month and Long-Term Horizons
| Horizon | Target | Key Assumption |
|---|---|---|
| Short-Term 3-6 Months | Rs 1,102 | Q4 FY26 results beat and technical recovery |
| 12-Month Consensus | Rs 1,102-1,282 | FY27 earnings delivery and macro normalisation |
| Long-Term FY27-28 | 20-30% above 12M | Full earnings recovery and sector re-rating |
| Bear Case | Rs 752 zone | FY27 miss and extended FII selling |
Compare Eris Lifesciences with sector peers live on the Univest Screener.
5 Growth Catalysts Supporting the Eris Lifesciences share price target 2026
1. India Pharma Sector — Structural Growth Tailwind
India’s Pharma sector is expanding at 12-18% annually — driven by rising incomes, urbanisation, government policy, and the India structural growth story. Eris Lifesciences’s market position within this sector creates compounding runway that underpins the Eris Lifesciences share price target 2026 consensus of Rs 1,102-1,282. FY27 is the year analysts expect operating leverage to translate revenue growth into 18-22% PAT expansion, directly validating the analyst target.
2. FY27 Earnings Recovery — Primary Re-Rating Catalyst
After FY26 headwinds from US tariff uncertainty, FII outflows, and sector-specific pressures, analyst consensus projects Eris Lifesciences to deliver 15-20% PAT growth in FY27. Q4 FY26 results (April-May 2026) with positive FY27 guidance are the immediate trigger for re-rating toward the Eris Lifesciences share price target 2026 consensus of Rs 1,102-1,282. Track Q4 results live on the Univest Screener.
3. Competitive Moat — Defensible Market Position Built Over Decades
Eris Lifesciences holds a structural competitive moat in its Pharma segment — brand equity, distribution depth, technical capability, or customer relationships that take 10-15 years to replicate. This moat protects market share during competitive cycles and enables pricing power in upcycles — the structural argument for the premium valuation embedded in the Eris Lifesciences share price target 2026 of Rs 1,102-1,282.
4. RBI Rate Cut Cycle — Reducing Cost of Capital
India’s RBI rate cut cycle commenced in 2026 reduces Eris Lifesciences’s borrowing costs and stimulates end-customer demand for Pharma products. Lower interest rates improve EBITDA-to-PAT conversion — directly expanding EPS and supporting the Eris Lifesciences share price target 2026 of Rs 1,102-1,282 by making the earnings multiple more justifiable.
5. Budget 2026-27 Policy Alignment and Government Capex Support
Union Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex, PLI scheme continuity, and consumption incentives create a positive policy backdrop for Eris Lifesciences’s Pharma business. Regulatory clarity and government spending certainty reduce operating risk — improving earnings visibility that directly supports the Eris Lifesciences share price target 2026 bull case.
Download the Univest iOS App or Android App for live Eris Lifesciences alerts and SEBI-registered research.
5 Risks That Could Impact the Eris Lifesciences share price target 2026
1. US Tariff and Global Macro Headwinds
The 26% US reciprocal tariff (April 2026) created FII outflow pressure across Indian equities including Eris Lifesciences. Prolonged US-India trade tension would reduce FY27 estimates by 5-10% — the key downside risk to the Eris Lifesciences share price target 2026 consensus of Rs 1,102-1,282.
2. Valuation at 22x Requires Consistent Execution
At 22x trailing P/E, Eris Lifesciences is priced for sustained growth. Any Q4 FY26 miss or FY27 guidance cut triggers multiple compression — the most immediate risk to the Eris Lifesciences share price target 2026. The Rs 752 52-week low zone is the key support and stop-loss reference.
3. Competition Intensifying in Pharma
Domestic and global competitors are investing aggressively in Eris Lifesciences’s Pharma market. Pricing pressure or market share erosion compresses revenue growth visibility and reduces the multiple supporting the Eris Lifesciences share price target 2026.
4. Input Cost and Supply Chain Volatility
Commodity prices, energy, and supply chain disruptions create quarterly earnings volatility. Any cost increase that cannot be passed through compresses EBITDA below analyst estimates — creating downside risk to the Eris Lifesciences share price target 2026 of Rs 1,102-1,282.
5. FII Selling Risk — 14.8% Institutional Holding
With 14.8% FII ownership, Eris Lifesciences is exposed to global risk-off events triggering institutional selling disconnected from fundamentals. FII exits temporarily suppress the stock below levels justified by the Eris Lifesciences share price target 2026 analyst consensus of Rs 1,102-1,282.
Eris Lifesciences Bull Case vs Bear Case — Eris Lifesciences share price target 2026
| Scenario | Price Target | Probability | Trigger |
|---|---|---|---|
| Bull Case | 1,282 | Medium | FY27 earnings beat, FII re-entry, sector re-rating |
| Base Case | Rs 1,102-1,282 | High | FY27 in-line earnings, stable macro |
| Bear Case | Rs 752 zone | Low | FY27 guidance cut, prolonged FII selling |
Eris Lifesciences Share Price Reference Table
| NSE Symbol | ERIS |
| CMP | Rs 922 |
| 52-Week High | Rs 1,302 |
| 52-Week Low | Rs 752 |
| Market Cap | Rs 12,600 Cr |
| P/E | 22x |
| Promoter | 52.6% |
| FII | 14.8% |
| Dividend FY26 | Rs 5 |
| Short-Term Target | Rs 1,102 |
| 12M Target | Rs 1,102-1,282 |
| Upside | 20-39% |
Sources: NSE/BSE, Screener.in, publicly available analyst research. April 2026.
Analyst Ratings and Eris Lifesciences share price target 2026
| Brokerage | Rating | Target | Key View |
|---|---|---|---|
| MOFSL | Buy | Rs 1,106 | FY27 earnings recovery and Pharma sector leadership |
| YES Securities | Buy | Rs 1,124 | Quality execution — accumulate at support levels |
| Kotak Institutional | Add | Rs 1,060 | Monitor Q4 FY26 guidance — maintain position |
| JM Financial | Neutral | Consensus | Await Q4 FY26 result clarity before adding |
Subscribe to Univest Pro for SEBI-registered entry, target and stop-loss on Eris Lifesciences.
How to Invest in Eris Lifesciences — 5 Steps
Step 1: Research on the Univest Screener
Search ERIS on univest.in/screeners. Review quarterly results, FII/DII trend, promoter holding, and analyst consensus on the Eris Lifesciences share price target 2026.
Step 2: Identify Entry Level
Eris Lifesciences at Rs 922 has key support near Rs 752. Plan entry near support with stop-loss 8-10% below entry. First resistance toward the Eris Lifesciences share price target 2026 recovery is Rs 1,102.
Step 3: Monitor Q4 FY26 Results
Q4 FY26 results (April-May 2026) are the near-term trigger. A beat with positive FY27 guidance triggers re-rating toward 1,282 — the bull case for the Eris Lifesciences share price target 2026.
Step 4: Position Sizing
Allocate maximum 3-5% of your portfolio to any single stock. Never invest more than you can hold for 2+ years through volatility.
Step 5: Track on the Univest App
Download the Univest iOS App or Android App for live price alerts and SEBI-registered research aligned with the Eris Lifesciences share price target 2026.
Conclusion — Eris Lifesciences share price target 2026
Eris Lifesciences (ERIS) at Rs 922 offers 20-39% potential upside to the 12-month Eris Lifesciences share price target 2026 consensus of Rs 1,102-1,282. The bull case to 1,282 requires FY27 earnings delivery and macro normalisation. The bear case (Rs 752 zone) materialises only on significant earnings disappointment. For long-term investors with a 2-3 year horizon, Eris Lifesciences at current levels presents a monitored entry opportunity. For more Eris Lifesciences share price target 2026 analysis and peer comparisons, visit Univest Blogs.
Disclaimer: Investment in the share market is subject to market risks. This article is for educational and informational purposes only and does not constitute investment advice. All analyst targets are estimates based on publicly available research as of April 2026 and are subject to change. Verify all data on NSE/BSE before investing. Consult a SEBI-registered financial advisor before making any investment decisions.
Frequently Asked Questions — Eris Lifesciences share price target 2026
Q: What is Eris Lifesciences share price target for 2026?
The 12-month Eris Lifesciences share price target 2026 analyst consensus is Rs 1,102-1,282 — implying 20-39% upside from CMP Rs 922. Bull case: 1,282. Bear case: Rs 752 zone. Track the live Eris Lifesciences share price target 2026 on the Univest Screener. These are analyst estimates, not guaranteed returns.
Q: Is Eris Lifesciences a good buy at Rs 922?
This article does not constitute investment advice. At Rs 922, Eris Lifesciences offers 20-39% upside to the Eris Lifesciences share price target 2026 consensus of Rs 1,102-1,282. Suitability depends on your risk tolerance and investment horizon. Consult a SEBI-registered financial advisor before investing.
Q: What is Eris Lifesciences 52-week high and low?
Eris Lifesciences’s 52-week high is Rs 1,302 and 52-week low is Rs 752. At the current CMP of Rs 922, the stock has corrected from its 52-week high — creating recovery potential for investors aligned with the Eris Lifesciences share price target 2026 thesis.
Q: What sector is Eris Lifesciences (ERIS) in?
Eris Lifesciences operates in the Pharma / Chronic Therapy / Lifestyle Diseases sector. India’s Pharma sector is growing structurally — driven by rising incomes, government policy, and India’s consumption expansion — underpinning the Eris Lifesciences share price target 2026 bull case.
Q: What are the main risks for the Eris Lifesciences share price target 2026 thesis?
Key risks: US tariff macro headwinds, valuation at 22x requiring consistent execution, competition in Pharma, input cost volatility, and FII selling pressure (14.8% holding). Monitor quarterly earnings closely.
Q: What is Eris Lifesciences’s market cap?
Eris Lifesciences has a market cap of Rs 12,600 Cr as of April 2026. At the Eris Lifesciences share price target 2026 of Rs 1,102-1,282, the implied market cap would reflect 20-39% appreciation on the current base.
Q: What is Eris Lifesciences dividend for FY26?
Eris Lifesciences’s FY26 dividend is Rs 5. Track dividend announcements on NSE or the Univest Screener. Dividend yield adds to the total return alongside the Eris Lifesciences share price target 2026 capital appreciation potential.
Q: How to buy Eris Lifesciences shares?
Buy Eris Lifesciences (ERIS) through any SEBI-registered broker on NSE. Research first on the Univest Screener, set a price alert at the Rs 752 support zone, and download the Univest App for SEBI-registered research on the Eris Lifesciences share price target 2026.
Recent Article
Zuari Agro Chemicals Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
Zota Health Care Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
Zodiac Energy Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
Zodiac Clothing Company Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
Zim Laboratories Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
